WEGOVY
PeakNDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
WEGOVY by Novo Nordisk is glp-1 analogue with 94% sequence homology to human glp-1. Approved for combination with a reduced calorie diet, increased physical activity: • to reduce the risk of major adverse cv events (cv death, non-fatal myocardial infarction and 4 more indications. First approved in 2021.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WEGOVY is a subcutaneous solution approved in 2021 by Novo Nordisk for weight management. The product is currently in peak commercial lifecycle stage. Mechanism of action and specific indications are not disclosed in available data.
Peak14.4 years to LOE
Peak-stage product with established market presence; brand teams typically maintain mid-to-large size with focus on market penetration and managed care strategies.
Mechanism of Action
GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake, and the GLP-1 receptor is present in…
Indications (7)
Worked on WEGOVY at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.